Updates on Chronic Rhinosinusitis With Nasal Polyps Evolving Best Practices for Patient Management

Cecelia Damask, DO, FAAOA; Matthew W. Ryan, MD

This activity is jointly provided by Global Education Group and Integritas Communications.


This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.



Cecelia Damask, DO, FAAOA
Medical Director
Lake Mary ENT and Allergy
Lake Mary, Florida

Matthew W. Ryan, MD
Vice Chair for Education and Quality
Department of Otolaryngology
University of Texas Southwestern Medical Center
Dallas, Texas

Program Overview

Expert faculty shine the spotlight on chronic rhinosinusitis with nasal polyps (CRSwNP), a disease associated with well-documented medical, psychological, social, and economic burdens. Using a case-based approach, faculty provide practical recommendations on how to best evaluate a patient’s symptoms, including the use of biomarkers to identify disease phenotypes and endotypes that can shape management decisions. Faculty examine various traditional medical and surgical treatments of CRSwNP, as well as indications for the use of biologic agents.

Target Audience

The educational design of this activity addresses the needs of allergy, immunology, and otolaryngology specialists involved in the treatment of patients with CRSwNP.

Educational Objectives

After completing this activity, the participant should be better able to:

  1. Discuss clinically relevant pathophysiologic factors in the development and persistence of CRSwNP
  2. Assess patients with CRSwNP for disease phenotypes, endotypes, symptom control, and ongoing treatment responses
  3. Describe the mechanistic profiles and clinical trial data with newer targeted medications for CRSwNP
  4. Prescribe treatment regimens for patients with CRSwNP that reflect symptom burden, endotypes, comorbidities, and shared clinical decision making

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on November 13, 2020 and is valid for 1 year. Requests for credit must be made no later than November 13, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Instructions to Receive Credit

In order to receive credit for this activity, the participant must review the activity, complete and receive at least a 70% score on the posttest, and complete the evaluation form.

System Requirements

Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), or Firefox

MAC OS 10.2.8
Internet Explorer is not supported on the Macintosh.

Fee Information

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Cecelia Damask, DO, FAAOA: Consultant/Contractor: AstraZeneca plc, Novartis Pharmaceutical Corporation. Grants/Research Support and Speakers Bureau: AstraZeneca plc, GlaxoSmithKline plc, OptiNose US, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC. Honoraria: ALK-Abelló A/S, Audigy Medical. Advisory Board: AstraZeneca plc, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC. Book Royalty: Thieme Medical Publishers, Inc.

Matthew W. Ryan, MD: Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Rose O’Connor, PhD: Nothing to disclose
Jim Kappler, PhD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 11/13/2021

type POC201